贝伐单抗的免疫效应：一石二鸟。
Immune effects of bevacizumab: killing two birds with one stone.
作者信息
Elamin Yasir Y, Rafee Shereen, Toomey Sinead, Hennessy Bryan T
机构信息
Department of Medical Oncology, Royal College of Surgeons, Beaumont Hospital, Dublin, Ireland,
出版信息
Cancer Microenviron. 2015 Apr;8(1):15-21. doi: 10.1007/s12307-014-0160-8. Epub 2014 Oct 18.
Abstract
Angiogenesis or new vessel formation is essential for tumour growth and progression. Therefore, targeting angiogenesis has been an attractive strategy in the treatment ofcancer. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody thattargets vascular endothelial growth factor-A (VEGF-A) - a key molecular player inangiogenesis. Bevacizumumab has shown clinical efficacy in phase III clinical trials inseveral advanced solid malignancies. The clinical efficacy of bevacizumumab isprimarily due to its antiangiogenic effects; however, there are direct antitumor effectsand immunomodulatory effects. Enhancing the immune system to restore itsantitumour activity has been utilized successfully in clinical setting. In this article we willdiscuss the possible immunomodulatory effects of the most clinically usedantiangiogenic agent; bevacizumumab.
摘要
血管生成或新血管形成对于肿瘤的生长和进展至关重要。因此，靶向血管生成一直是癌症治疗中一种有吸引力的策略。贝伐单抗是一种重组人源化单克隆IgG1抗体，其靶向血管内皮生长因子-A（VEGF-A）——血管生成中的关键分子。贝伐单抗在多种晚期实体恶性肿瘤的III期临床试验中已显示出临床疗效。贝伐单抗的临床疗效主要归因于其抗血管生成作用；然而，它也有直接的抗肿瘤作用和免疫调节作用。增强免疫系统以恢复其抗肿瘤活性已在临床环境中成功应用。在本文中，我们将讨论临床上最常用的抗血管生成药物贝伐单抗可能的免疫调节作用。
相似文献
1
Immune effects of bevacizumab: killing two birds with one stone.
Cancer Microenviron. 2015 Apr;8(1):15-21. doi: 10.1007/s12307-014-0160-8. Epub 2014 Oct 18.
2
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Curr Med Chem. 2006;13(16):1845-57. doi: 10.2174/092986706777585059.
3
The role of antiangiogenetic agents in the treatment of breast cancer.
Curr Med Chem. 2011;18(33):5022-32. doi: 10.2174/092986711797636072.
4
Integration of novel agents in the treatment of colorectal cancer.
Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0.
5
Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de.
6
A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
J Biol Chem. 2017 Mar 3;292(9):3552-3567. doi: 10.1074/jbc.M116.747766. Epub 2016 Dec 29.
7
Bevacizumab: antiangiogenic cancer therapy.
Drugs Today (Barc). 2005 Jan;41(1):23-36. doi: 10.1358/dot.2005.41.1.875776.
8
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Clin Lung Cancer. 2008;9 Suppl 3:S100-8. doi: 10.3816/CLC.2008.s.015.
9
Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. doi: 10.1053/sonc.2002.37265.
10
Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Clin Cancer Res. 2008 Dec 15;14(24):8123-31. doi: 10.1158/1078-0432.CCR-08-0025.
引用本文的文献
1
Promoting Immune Response of Human Vascular Endothelial Cells by Bevacizumab: Insights into the Immune Supportive Role of Anti-VEGF Therapy.
Int J Mol Sci. 2025 Jun 29;26(13):6280. doi: 10.3390/ijms26136280.
2
Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal Cancer.
Int J Mol Sci. 2025 Mar 12;26(6):2556. doi: 10.3390/ijms26062556.
3
Recurrent adamantinomatous craniopharyngioma stabilized with tocilizumab and bevacizumab: illustrative case.
J Neurosurg Case Lessons. 2025 Jan 13;9(2). doi: 10.3171/CASE24410.
4
Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment.
Int J Biol Sci. 2024 Jul 15;20(10):3911-3922. doi: 10.7150/ijbs.93697. eCollection 2024.
5
Cancer Immunotherapy with "Vascular-Immune" Crosstalk as Entry Point: Associated Mechanisms, Therapeutic Drugs and Nano-Delivery Systems.
Int J Nanomedicine. 2024 Jul 19;19:7383-7398. doi: 10.2147/IJN.S467222. eCollection 2024.
6
Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
Cancers (Basel). 2023 Oct 28;15(21):5189. doi: 10.3390/cancers15215189.
7
Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.
Cancer Drug Resist. 2023 Aug 2;6(3):517-546. doi: 10.20517/cdr.2023.33. eCollection 2023.
8
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2023-006680.
9
Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma.
Cancers (Basel). 2023 Jan 30;15(3):863. doi: 10.3390/cancers15030863.
10
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
J Hematol Oncol. 2022 Jun 11;15(1):80. doi: 10.1186/s13045-022-01298-0.
本文引用的文献
1
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.
J Immunother Cancer. 2013 Jul 15;1:10. doi: 10.1186/2051-1426-1-10. eCollection 2013.
2
VEGF regulates region-specific localization of perivascular bone marrow-derived cells in glioblastoma.
Cancer Res. 2014 Jul 15;74(14):3727-39. doi: 10.1158/0008-5472.CAN-13-3119. Epub 2014 May 12.
3
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.
Nat Med. 2014 Jun;20(6):607-15. doi: 10.1038/nm.3541. Epub 2014 May 4.
4
Improved survival with bevacizumab in advanced cervical cancer.
N Engl J Med. 2014 Feb 20;370(8):734-43. doi: 10.1056/NEJMoa1309748.
5
Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment.
Oncoimmunology. 2012 Nov 1;1(8):1445-1447. doi: 10.4161/onci.21318.
6
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2.
Br J Cancer. 2012 Nov 20;107(11):1869-75. doi: 10.1038/bjc.2012.468.
7
VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Cancer Res. 2013 Jan 15;73(2):539-49. doi: 10.1158/0008-5472.CAN-12-2325. Epub 2012 Oct 29.
8
VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue.
Blood. 2012 Nov 29;120(23):4653-62. doi: 10.1182/blood-2012-04-421040. Epub 2012 Sep 10.
9
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.
10
Treatment selection in metastatic renal cell carcinoma: expert consensus.
Nat Rev Clin Oncol. 2012 Apr 10;9(6):327-37. doi: 10.1038/nrclinonc.2012.59.
Zotero 插件